Cronos Group Inc. (CRON)
Why Cannabis Stocks Are Trading Lower Today
Shares of several cannabis companies such as Canopy Growth Corporation (NYSE: CGC), Tilray, Inc. (NASDAQ: TLRY) and Cronos Group Inc. (NASDAQ: CRON) are …
Cronos Group replaces CEO with consumer packaged goods veteran
Cronos Group has become the latest Canadian cannabis company to shake up its top ranks, replacing former CEO Mike Gorenstein with experienced consumer packaged goods executive Kurt Schmidt. The announcement comes just one day after major Canadian producer Aurora Cannabis announced its new CEO. Schmidt’s appointment was the result of a year-long search for “an […] Cronos Group replaces CEO with consumer packaged goods veteran is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
Why Cannabis Is An Afterthought In The Biden-Trump Election
The S&P 500 has rallied hard off the index's March lows and is back at new all-time highs. Unfortunately for cannabis investors, cannabis stocks like Canopy Growth Corp (NYSE: CGC ), Cronos Group Inc (NASDAQ: CRON ) and Aurora Cannabis Inc (NYSE: ACB ) are still down sharply in 2020. No Pre-Election Highs For Cannabis Stocks: One of the most disappointing observations for cannabis stock investors is how poorly the stocks are performing with a little more than two months remaining until the U.S. presidential election. Cannabis legalization appears to be an afterthought at this point for both Democratic nominee Joe Biden and incumbent Republican President Donald Trump, DataTrek Research co-founder Jessica Rabe said Tuesday. Expecting Trump and the Republican Party to change their tune on cannabis may have been … Full story available on Benzinga.com
Top Wall Street analysts say these are the 7 cannabis stocks to bet on now that will benefit if Biden defeats Trump in November
Wall Street analysts say a Democratic sweep in November that puts Joe Biden in the White House and the party in control of the Senate could be a boon for cannabis stocks. Analysts at CIBC and Cowen picked 7 stocks to bet on that would benefit if the Democrats win, including Green Thumb Industries, Curaleaf, and Canopy Growth. Visit Business Insider's homepage for more stories . As public support for cannabis reform picks up steam in the US, Wall Street analysts say signs are pointing to a turnaround in the formerly troubled sector, especially as a few companies posted solid earnings over the past week. Vivien Azer, a cannabis-industry analyst at the investment bank Cowen, said in an August 7 note that Democratic nominee Joe Biden's polling lead is a "positive sign for the industry." That, on top of the coronavirus-pandemic-induced sales bump , has upped investor confidence in the sector after months of stock declines and layoffs. While Azer says that real power on cannabis reform rests in the Senate, rather than the White House, "we reiterate the view that a Democratic sweep means 2021 legalization." Read more : The CEO of Canopy Growth lays out 3 reasons he's 'never been more bullish' on the cannabis industry John Zamparo, a cannabis-industry analyst at CIBC, said in a July 17 note that a Democratic victory in November could boost US firms as well as Canadian cannabis firms with interests in expanding to the US. "A clean sweep by the Democrats would, in our opinion, most benefit Canadian operators with strong balance sheets and US ambitions," Zamparo said.
The Case for Cronos Stock to Rise By 100%
Beaten and bruised, CRON stock has a chance to reverse course sharply over the next few months as its biggest headwinds turn into tailwinds.
The Week In Cannabis: FDA Approves Epidiolex, Brett Favre Joins The Industry, Stocks In Red
In a week where markets were up, cannabis stocks were mostly declining. The week started off on a good note, with GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) and Greenwich Biosciences Inc. jointly announcing FDA approval for Epidiolex, an oral solution aimed to manage seizures related to tuberous sclerosis complex. The companies said the age range includes patients one year of age and older. Besides the new indication, EPIDIOLEX, which is plant-derived CBD medicine, can also help those suffering from seizures linked to Lennox-Gastaut and Dravet syndromes. Initially, the medicine is approved by the FDA for treating both syndromes in patients two years of age and older. Illinois adult-use cannabis sales remained strong in July, hitting around $61 million. That’s a monthly increase of roughly 28%. In Michigan, speculation mounted around new cannabis licenses. According to some reports, starting Nov. 1, businesses and individuals aspiring a recreational marijuana license in Michigan may no longer need to be a medical marijuana license holder.
Cronos Group Inc. (CRON) Q2 2020 Earnings Call Transcript | The Motley Fool
CRON earnings call for the period ending June 30, 2020.
Cannabis Producer Cronos Plunges On $107M Loss, Says Pricing Pressures Drove Write-Downs
Cronos Group (NASDAQ: CRON ) opened Thursday morning at $6.62 a share, but quickly lost ground on the heels of an earnings report showing a second-quarter net loss of $107 million. Cronos also reported a $40-million impairment charge related to a cannabidiol deal with CBD brand Lord Jones and a $35.9-million noncash loss related to an investment from cigarette conglomerate Altria Group (NYSE: MO ). "In … Full story available on Benzinga.com
Cannabis Grower Cronos Group Stock Plunges on $107 Million Loss
Cronos’ results include a $40 million impairment charge related to the value of its investment in the U.S. cannabidiol brand Lord Jones and a $35.9 million noncash loss related to tobacco giant Altria Group’s investment in the company.
Cronos (CRON) Q2 Earnings: Key financials and quarterly highlights
Cronos Group Inc. (NASDAQ: CRON) reported second quarter 2020 earnings results today. Consolidated net revenues grew 29% year-over-year to $9.9 million, driven by continued growth in the adult-use Canadian cannabis market, sales from cannabis vaporizers and the Redwood acquisition. Net loss attributable to Cronos Group amounted to $106 million, or $0.31 per share, compared to […]
Cronos Group (CRON) earnings: expect 110% revenue growth
Cronos Group (CRON) is announcing earnings on May 09, 2019. What should you expect?
Is CRON flying too high?
Is Cron a good stock to buy now? Or should you sell it now? Here is the analysis by Finstead's Carla Olson for March 28.
Cronos (CRON) stock: still riding high
Cronos Group Inc. (CRON) shares are trading at $12.62, up 7%. The stock is trading almost 30% down from its recent peak of $13.75. What's driving CRON stock price? What's CRON stock price forecast?
Cronos Group (CRON) stock: trending positive, but is it overbought?
What's driving CRON stock price? What's CRON stock price forecast?
Cronos Group (CRON) price speculation: what's next?
Cronos Group (CRON) stock was up 14% post market hours today. The stock is still significantly below this year's peak, $9.91, achieved in the March time frame. So what is the CRON stock price forecast?